Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Myeloma and heart failure…heart failure and myeloma. One can cause the other and common cancer therapies can cause heart failure. So what’s a survivor of either/or/both myeloma and heart failure to do?
I try to link research in each blog post on PeopleBeatingCancer but medical doctors are lousy writers.
“Despite advances in understanding the interplay between immune system dysregulation, tissue inflammation, and oxidative stress in cancer-induced cardiac dysfunction, clinical recognition and systematic investigation of these phenomena remain limited…”
I’m pretty sure that the sentence pasted above says that while medicine is trying to learn about the interplay of cancer and heart failure, there is little recognition of the relationship between the two and even less research into the issue.
To me, a long-term myeloma survivor who has chemotherapy-induced cardiomyopathy, the sentence means that conventional medicine has little to offer me in terms of research or actual therapies that can help me.
The answer then, is to continue what I’m doing to reduce my risk of
The content linked below is important. It is not simply cardiotoxic chemo that cancer patients need to look out for. It really is a full spectrum approach that is needed to understand cancer and heart failure.
Heart healthy nutrition, supplementation, moderate exercise, all are my go-to therapies. Yes, cardiology has many effective meds to offer the heart failure patient. Though I believe that our first step is nutrition, supplementation, etc.
“Abstract- The intricate relationship between cancer and cardiovascular diseases (CVD), notably heart failure (HF), is gaining attention in the medical field. This literature review explores the intricate interplay between cancer and CVD, particularly HF, emphasizing their significant impact on global mortality and comorbidity.
While preventive measures have contributed to reducing their incidence, challenges persist in predicting and managing cancer-related complications. This review article delves into various risk factors associated with both cancer and HF, including lifestyle factors, genetic predispositions, and immune system dysregulation.
It highlights emerging evidence suggesting a direct interaction between cancer and HF, with studies indicating an elevated risk of mortality from cancer in patients with HF and vice versa.
Pathological mechanisms such as inflammation, oxidative stress, and tissue hypoxia are implicated in cancer-induced cardiac dysfunction, underscoring the need for comprehensive clinical investigations and ethical considerations in patient care.
The review also discusses the potential role of biomarkers in risk assessment, early detection of cardiotoxicity, and understanding common pathophysiological links between cancer and HF, paving the way for multifaceted preventive and therapeutic approaches…
Stoltzfus et al. described a study amongst 7.5 million cancer patients and identified that those who were diagnosed <40 years of age were more likely to die of heart disease when diagnosed with
patients diagnosed >40 years of age were more likely to die from heart disease when diagnosed with
Ge et al. demonstrated that in a study involving 59,653, they evaluated the relationship between cancer and HF. In patients without cancer, the risk of mortality from cancer was higher (HR 1.36; 95% CI 1.09-1.69; P = 0.005); in patients with cancer, HF was associated with an elevated risk of death from cancer (HR 1.76; 95% CI 1.32-2.34; P < 0.001) [28]…
Conclusions- Cancer and CVD, particularly HF, stand out as among the most widely acknowledged contributors to mortality and comorbidity globally. While preventive measures have contributed to reducing the incidence of both conditions, the complexities of risk prediction and management persist, particularly in cancer-related complications. Despite advances in understanding the interplay between immune system dysregulation, tissue inflammation, and oxidative stress in cancer-induced cardiac dysfunction, clinical recognition and systematic investigation of these phenomena remain limited…
It is noteworthy that cancer, through its hypermetabolic state, can act as a sole risk factor for HF, further underscoring the intricate interplay between these two disease entities. Oncologists frequently refer patients for cardiological evaluation to assess risk and monitor treatment effects.
They may also reveal common pathophysiological links between cancer and HF, prompting multifaceted preventive and therapeutic approaches.”